Precision Diagnostic Solutions
At General Biologicals Corporation (GBC), we design, develop, and manufacture diagnostic tests, instruments, and digital solutions that transform the way clinicians and laboratories deliver care.
For over 40 years, GBC has been at the forefront of in-vitro diagnostics (IVD) innovation, combining scientific expertise with cutting-edge technology to improve health outcomes worldwide.
Innovating In-Vitro Diagnostics
Since our founding in 1984, GBC has led the development of hepatitis and retrovirus diagnostic solutions and expanded into oncology, infectious diseases, fertility, blood-borne viruses, and emerging pathogens.
By leveraging ELISA, CLIA, and real-time PCR platforms, we deliver precision diagnostic tools trusted by hospitals, clinical laboratories, and pharmaceutical companies in 40+ countries.
In-vitro diagnostics are critical tools for early detection, disease management, and preventive care. GBC’s solutions empower healthcare professionals to diagnose accurately, treat effectively, and improve patient outcomes.
Automated Diagnostic Systems
To enhance laboratory efficiency and accuracy, GBC has developed automated diagnostic instruments that integrate seamlessly with our IVD reagents and testing platforms.
Key Benefits of GBC Systems:
• Rapid turnaround times for high-volume testing
• Reliable and reproducible results
• Reduced manual workload for technicians
• Scalability for growing diagnostic needs
Our innovations, including the GBC AIO M160 multi-functional analyzer and CellBio™ CTC platform, streamline diagnostic workflows and enable laboratories to deliver better patient care faster.
